Latest Competition News

FirstWave reports a stable Q2 FY25 with no cash burn for the second consecutive quarter, maintaining cash reserves at $1.68 million while securing key client contract renewals and launching a promising new product.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

OpenLearning Limited reported a 23% year-on-year increase in SaaS annual recurring revenue to $2.335 million in Q4 FY24, driven by strong growth in AI-powered products and strategic partnerships. The company also cut net operating cash outflows by over half, signaling improved operational efficiency.

NEXION Group reported a robust 30% increase in cash receipts for Q2 FY25, driven by strong sales growth and new satellite sector contracts. The company is actively expanding its footprint in Southeast Asia while funding ongoing M&A activities through convertible notes.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

Syrah Resources faces significant operational disruption at its Balama graphite mine due to ongoing protests, declaring force majeure while advancing its US-based Vidalia facility amid strong EV market growth.

Appen's Q4 FY24 results reveal a robust 37% revenue increase excluding Google, alongside improved EBITDA profitability, driven by generative AI projects and strategic cost management.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.

Asset Vision Co Limited has reported a robust Q2 FY25, marked by significant revenue growth, improved cash flow, and effective cost management, positioning the company well for continued expansion.

Credit Corp Group Limited has announced a fully franked ordinary dividend of AUD 0.32 per share for the six months ending December 2024, signaling steady shareholder returns.

BlueBet Holdings has delivered positive EBITDA for the first half of FY25 ahead of schedule, driven by strategic customer reactivation and enhanced platform efficiencies following its merger with betr.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.